Zydus Cadila Launches Nudoxa Chemotherapy For Treating Aggressive Cancer
This article was originally published in PharmAsia News
Zydus Cadila announced it has launched its Nudoxa (doxorubiein) drug for treating cancer, using a new type of drug-delivery system. The drug is a variant of the liposomal doxorubiein drug that offers cancer therapy against aggressive and malignant tumors without the accompanying side effects. The drug is made by Zydus-BSV Pharma, a joint venture of Zydus Cadila and Bharat Serums and Vaccines, and is used as a chemotherapy for treating various cancers, primarily breast cancer. (Click here for more
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.